Shares of Germany's Epigenomics were hammered early today when Roche announced it was ending a collaboration to develop new cancer screening tests after determining Epigenomics' data did not meet its standards. Epigenomics CFO Oliver Schacht told reporters that the company was looking to license its programs in different cancers to different partners, rather than as a group. New deals are likely to take three to six months to complete. In the meantime, its shares plunged more than 50 percent on the news.
- check out Roche's announcement [1] on the decision
- here's the report [2] on Epigenomics from MarketWatch
Related Articles:
Roche, Xenon ink pact on anemia therapies. Report [3]
Roche walks away from daclizumab pact. Report [4]
Roche drops out of PDL program. Report [5]
Links:
[1] http://www.fiercebiotech.com/node/4952
[2] http://www.marketwatch.com/news/story/shares-german-biotech-epigenomics-shares/story.aspx?guid=%7BF4E43DBD-FC48-4013-B83A-10F225833CA6%7D
[3] http://www.fiercebiotech.com/story/roche-and-xenon-ink-pact-on-anemia-therapies/2006-12-07
[4] http://www.fiercebiotech.com/story/roche-walks-away-from-daclizumab-pact/2006-11-22
[5] http://www.fiercebiotech.com/story/spotlight-roche-drops-out-of-pdl-program/2006-08-30